Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Price, Quote, News and Overview

NASDAQ:QNRX - Nasdaq - US74907L4095 - ADR - Currency: USD

8.53  -0.54 (-5.95%)

QNRX Quote, Performance and Key Statistics

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (5/30/2025, 8:00:01 PM)

8.53

-0.54 (-5.95%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High54.95
52 Week Low5.01
Market Cap5.02M
Shares588.20K
Float548.32K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO11-01 1989-11-01


QNRX short term performance overview.The bars show the price performance of QNRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

QNRX long term performance overview.The bars show the price performance of QNRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of QNRX is 8.53 USD. In the past month the price increased by 29.14%. In the past year, price decreased by -68.64%.

QUOIN PHARMACEUTICALS LT-ADR / QNRX Daily stock chart

QNRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 97.66 35.00B
ONC BEONE MEDICINES LTD-ADR 6.28 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About QNRX

Company Profile

QNRX logo image Quoin Pharmaceuticals Ltd is a IL-based company operating in Biotechnology industry. Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Company Info

QUOIN PHARMACEUTICALS LT-ADR

23 Hata'as Street

Kfar Saba IL

CEO: Shai Yarkoni

Employees: 4

QNRX Company Website

QNRX Investor Relations

Phone: 97299741444

QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ

What is the stock price of QUOIN PHARMACEUTICALS LT-ADR today?

The current stock price of QNRX is 8.53 USD. The price decreased by -5.95% in the last trading session.


What is the ticker symbol for QUOIN PHARMACEUTICALS LT-ADR stock?

The exchange symbol of QUOIN PHARMACEUTICALS LT-ADR is QNRX and it is listed on the Nasdaq exchange.


On which exchange is QNRX stock listed?

QNRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for QUOIN PHARMACEUTICALS LT-ADR stock?

8 analysts have analysed QNRX and the average price target is 61.4 USD. This implies a price increase of 619.86% is expected in the next year compared to the current price of 8.53. Check the QUOIN PHARMACEUTICALS LT-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is QUOIN PHARMACEUTICALS LT-ADR worth?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 5.02M USD. This makes QNRX a Nano Cap stock.


How many employees does QUOIN PHARMACEUTICALS LT-ADR have?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 4 employees.


What are the support and resistance levels for QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a support level at 6.69 and a resistance level at 8.68. Check the full technical report for a detailed analysis of QNRX support and resistance levels.


Should I buy QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock pay dividends?

QNRX does not pay a dividend.


When does QUOIN PHARMACEUTICALS LT-ADR (QNRX) report earnings?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX)?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-48.85).


QNRX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to QNRX. When comparing the yearly performance of all stocks, QNRX is a bad performer in the overall market: 93.6% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QNRX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to QNRX. QNRX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QNRX Financial Highlights

Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -48.85. The EPS increased by 80.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -80.64%
ROE -176.3%
Debt/Equity 0.47
Chartmill High Growth Momentum
EPS Q2Q%83.27%
Sales Q2Q%N/A
EPS 1Y (TTM)80.8%
Revenue 1Y (TTM)N/A

QNRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to QNRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners18.89%
Ins Owners16.57%
Short Float %N/A
Short Ratio0
Analysts
Analysts82.5
Price Target61.4 (619.81%)
EPS Next Y55.05%
Revenue Next YearN/A